🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

CILK1

MOLECULAR TARGET

ciliogenesis associated kinase 1

UniProt: Q9UPZ9NCBI Gene: 2285824 compounds

CILK1 (ciliogenesis associated kinase 1) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CILK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2dinaciclib3.8747
3midostaurin3.8546
4silmitasertib3.7843
5abemaciclib3.6638
6nintedanib3.6136
7bms 3870323.4731
8tae 6843.4330
9fedratinib3.4029
10at 75193.3327
11lestaurtinib3.0420
12pacritinib3.0420
13pf 037583093.0019
14ruboxistaurin2.9418
15momelotinib2.8917
16milciclib2.7715
17sotrastaurin2.7715
18pha 6657522.7114
19kw 24492.6413
20ast 4872.5612
21su 0148132.208
22enzastaurin2.087
23rg 5472.087
24pictilisib0.691

About CILK1 as a Drug Target

CILK1 (ciliogenesis associated kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented CILK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CILK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.